Can we efficiently and safely combine a pan-class I phosphatidylinositol-3-kinase inhibitor with paclitaxel in metastatic breast cancer?

Despite all therapeutic advances, patients with advanced and metastatic breast cancer (MBC) remain incurable in most cases. The majority of these patients progress after one to two years on first line systemic chemotherapy or endocrine therapy (1,2). Hence, there is a crucial need for more efficient and less toxic therapies in the first line setting and beyond to delay the time to progression and to improve outcomes.